Get the latest tech news
Chan Zuckerberg Initiative’s rBio uses virtual cells to train AI, bypassing lab work
The Chan Zuckerberg Initiative unveils rBio, a groundbreaking AI model that simulates cell biology without lab experiments to accelerate drug discovery and disease research.
The Chan Zuckerberg Initiative announced Thursday the launch of rBio, the first artificial intelligence model trained to reason about cellular biology using virtual simulations rather than requiring expensive laboratory experiments — a breakthrough that could dramatically accelerate biomedical research and drug discovery. The announcement represents a significant milestone for CZI’s ambitious goal to “cure, prevent, and manage all disease by the end of this century.” Under the leadership of pediatrician Priscilla Chan and Meta CEO Mark Zuckerberg, the $6 billion philanthropic initiative has increasingly focused its resources on the intersection of artificial intelligence and biology. For an organization that began with the audacious goal of curing all diseases by the century’s end, rBio offers something that has long eluded medical researchers: a way to ask biology’s hardest questions and get scientifically grounded answers in the time it takes to type a sentence.
Or read this on Venture Beat